Director/PDMR Shareholding

March 7, 2014

Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified that Matthew Emmens, the Company’s Chairman, sold 36,375 Ordinary Shares in the Company (“Shares”) today at an average sale price of £32.8309. The Shares were sold on the London Stock Exchange.

Following the above transaction, Mr Emmens holds 20,399 Shares and 5,872 American Depositary Shares in the Company (“ADSs”). Each ADS represents three Shares.

This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary

 

For further information please contact:

Investor Relations
Laurie Stelzer
lstelzer@shire.com
+1 781 482 0733

Eric Rojas
erojas@shire.com
+1 781 482 0999

Sarah Elton-Farr
seltonfarr@shire.com
+44 1256 894157

 

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

www.shire.com

Click here for the PDF version of this press release.